Steen Klysner
Nessuna posizione attualmente
Profilo
Steen Søren Klysner served as Chief Executive Officer at Nordic Vaccine A, ExpreS2ion Biotechnologies ApS, and Expres2ion Biotech Holding AB.
He was also the Chief Executive Officer at Amarna Therapeutics BV from 2020 to 2023.
Additionally, he served as Chairman at Minervax ApS, Director & Vice President at Pharmexa A, Director at Nykode Therapeutics ASA, Principal at Novo Nordisk A, Vice President-Preclinical Research & Development at ALK-Abello A, and Vice President-Research & Development at Allergopharma Srl.
Klysner holds a doctorate degree from the Technical University of Denmark and undergraduate and graduate degrees from the University of Copenhagen.
Precedenti posizioni note di Steen Klysner
| Società | Posizione | Fine |
|---|---|---|
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Amministratore Delegato | 07/06/2023 |
| EXPRES2ION BIOTECH HOLDING AB | Amministratore Delegato | 20/12/2019 |
Allergopharma Srl
 Allergopharma Srl Pharmaceuticals: MajorHealth Technology Allergopharma SpA manufactures pharmaceuticals and chemicals products. The company is headquartered in Vimodrone, Italy. | Corporate Officer/Principal | - |
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Amministratore Delegato | - |
Nordic Vaccine A/S
 Nordic Vaccine A/S Pharmaceuticals: MajorHealth Technology Nordic Vaccine A/S engages in the development and commercialization of vaccines for prophylactic and therapeutic use. It offers Posintro that combines delivery and immunological properties for the development of prophylactic and therapeutic vaccines. The firm also provides needle free delivery systems, including TransVac, a novel patch system for pain-free, non-invasive, and transdermal delivery of vaccines. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. | Presidente | - |
Formazione di Steen Klysner
| University of Copenhagen | Graduate Degree |
| Technical University of Denmark | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| ALK-ABELLÓ A/S | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| NYKODE THERAPEUTICS | Health Technology |
| EXPRES2ION BIOTECH HOLDING AB | Health Technology |
| Aziende private | 6 |
|---|---|
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Nordic Vaccine A/S
Nordic Vaccine A/S Pharmaceuticals: MajorHealth Technology Nordic Vaccine A/S engages in the development and commercialization of vaccines for prophylactic and therapeutic use. It offers Posintro that combines delivery and immunological properties for the development of prophylactic and therapeutic vaccines. The firm also provides needle free delivery systems, including TransVac, a novel patch system for pain-free, non-invasive, and transdermal delivery of vaccines. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Health Technology |
Allergopharma Srl
Allergopharma Srl Pharmaceuticals: MajorHealth Technology Allergopharma SpA manufactures pharmaceuticals and chemicals products. The company is headquartered in Vimodrone, Italy. | Health Technology |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
- Borsa valori
- Insiders
- Steen Klysner